GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets had a difficult start to 2025; with high levels of volatility in all of the main indices. The Value Fund finished the first quarter +3.0% net of fees and expenses. For the first quarter, the S&P/TSX returned +1.5%, the S&P500 returned -4.2%, and the Nasdaq returned –10.2%. The markets fell around 10% this past week as a result of President Trump’s April 2 “Liberation Day” tariff announcement. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.
In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as ICON Public Limited Company (NASDAQ:ICLR). Headquartered in Dublin, Ireland, ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization. The one-month return of ICON Public Limited Company (NASDAQ:ICLR) was -13.11%, and its shares lost 50.23% of their value over the last 52 weeks. On April 9, 2025, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $155.49 per share with a market capitalization of $12.567 billion.
GreensKeeper Asset Management stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2025 investor letter:
“We made one new purchase in the quarter: ICON Public Limited Company (NASDAQ:ICLR). ICLR is a leading contract research organization (CRO) based in Ireland that manages clinical trials for pharmaceutical and biotechnology companies worldwide. Despite some uncertainty driven by recent personnel changes at the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), we believe that new drugs and medical devices will continue to be developed, and scientific progress will continue. New drugs require rigorous clinical testing before reaching the market. As a leading CRO, ICLR will capture its fair share of clinical trials once the dust settles.”
A laboratory setting with a team of scientists working on a clinical trial.
ICON Public Limited Company (NASDAQ:ICLR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 46 hedge fund portfolios held ICON Public Limited Company (NASDAQ:ICLR) at the end of the fourth quarter which was 48 in the previous quarter. ICON Public Limited Company’s (NASDAQ:ICLR) fourth quarter revenue was $2.04 billion, represents a year-on-year decrease of 1.2%. While we acknowledge the potential of ICON Public Limited Company (NASDAQ:ICLR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
We covered ICON Public Limited Company (NASDAQ:ICLR) in another article, where we shared LVS Advisory’s views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.